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Background. It is generally accepted that CD8
+ T cell responses play an important role in control of immunodeficiency virus
replication. The association of HLA-B27 and -B57 with control of viremia supports this conclusion. However, specific correlates
of viral control in individuals expressing these alleles have been difficult to define. We recently reported that transient in vivo
CD8
+ cell depletion in simian immunodeficiency virus (SIV)-infected elite controller (EC) macaques resulted in a brief period of
viral recrudescence. SIV replication was rapidly controlled with the reappearance of CD8
+ cells, implicating that these cells
actively suppress viral replication in ECs. Methods and Findings. Here we show that three ECs in that study made at least
seven robust CD8
+ T cell responses directed against novel epitopes in Vif, Rev, and Nef restricted by the MHC class I molecule
Mamu-B*08. Two of these Mamu-B*08-positive animals subsequently lost control of SIV replication. Their breakthrough virus
harbored substitutions in multiple Mamu-B*08-restricted epitopes. Indeed, we found evidence for selection pressure mediated
by Mamu-B*08-restricted CD8
+ T cells in all of the newly identified epitopes in a cohort of chronically infected macaques.
Conclusions. Together, our data suggest that Mamu-B*08-restricted CD8
+ T cell responses effectively control replication of
pathogenic SIVmac239. All seven regions encoding Mamu-B*08-restricted CD8
+ T cell epitopes also exhibit amino acid
replacements typically seen only in the presence of Mamu-B*08, suggesting that the variation we observe is indeed selected by
CD8
+ T cell responses. SIVmac239 infection of Indian rhesus macaques expressing Mamu-B*08 may therefore provide an animal
model for understanding CD8
+ T cell-mediated control of HIV replication in humans.
Citation: Loffredo JT, Friedrich TC, Leo ´n EJ, Stephany JJ, Rodrigues DS, et al (2007) CD8
+ T Cells from SIV Elite Controller Macaques Recognize Mamu-
B*08-Bound Epitopes and Select for Widespread Viral Variation. PLoS ONE 2(11): e1152. doi:10.1371/journal.pone.0001152
INTRODUCTION
Several lines of evidence suggest that CD8
+ T cells play a key role in
immune control of immunodeficiency virus replication. The
reduction in acute viremia is associated with the appearance of
CD8
+ T cell responsesin both HIV-infected humans [1,2] and SIV-
infected macaques [3,4], though recent experiments suggest that
this reduction could also be due to the acute depletion of memory
CD4
+ T cells that are the preferred targets for infection [5,6].
Expression of particular HLA/MHC class I alleles is associated with
reduced plasma viremia and/or slower disease progression in
humans [7–12] and macaques [13–17]. CD8
+ T cell responses also
exert selective pressure on replicating viruses, resulting in the
emergence of variants that escape immune detection in both HIV
and SIV infection [18–27]. Most strikingly, transient depletion of
circulating CD8
+ lymphocytes in SIV-infected macaques results in
dramatic increases in plasma viremia [28–30]. These findings
suggest that inducing CD8
+ T cell responses will be an important
component of AIDS vaccine strategies. However, because most
HIV- and SIV-infected individuals mount CD8
+ T cell responses,
and the majority of these individuals progress to AIDS, it is clear
that thepresenceofstrongresponsesaloneisnotsufficienttocontrol
viral replication or delay disease progression. Therefore, it is
important to define attributes that might distinguish effective CD8
+
T cell responses from ineffective ones.
In the effort to define such correlates of control for CD8
+ T
cells, there has been considerable interest in ‘‘elite controllers’’
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levels below the detection threshold of current assays (,50 vRNA
copy Eq/ml plasma) [31]. Effective control of HIV replication in
some such individuals could be mediated by determinants other
than cellular immunity, such as infection with attenuated viruses
[32–35], polymorphisms in host genes outside the MHC [36–40],
or autoimmune antibodies directed against the CCR5 coreceptor
[41,42]. However, there is strong evidence suggesting that
particular CD8
+ T cell responses play a major role in effective
viremia control in at least some ECs. Vigorous CD8
+ T cell
responses have been observed in individuals with non-progressive
infection [43,44]. Investigation of the phenotypes of HIV-specific
CD8
+ T cells has suggested that controllers retain effector
functions that are lost in progressors [45–48]. The MHC class I
alleles HLA-B27 and HLA-B57/B*5801 are over-represented in
cohorts of ECs, suggesting that the cellular immune responses they
restrict contribute to immune containment of viral replication [7–
12]. In support of this suggestion, viral escape from the
immunodominant response to the HLA-B27-restricted epitope
Gag263–272KK10 has been associated with loss of control of viral
replication [21,49–51]. The role of viral evolution and particular
epitope-specific responses in control associated with HLA-B57,
however, remains less clear [52].
Studies of elite HIV control in humans are limited by drawbacks
inherent to research in populations infected with diverse virus
strains. An animal model of effective viremia control would
complement these studies by offering an example of successful
immune containment of pathogenic AIDS virus replication while
allowing direct control over key variables such as virus strain, host
genotype, and timing and route of infection. To this end, several
studies have noted relationships between MHC class I genotypes
and effective control of viremia in cohorts of SIV-infected rhesus
macaques that mirror those seen in human EC cohorts. Expres-
sion of the common MHC class I allele Mamu-A*01 has been
observed to lower set-point viremia in vaccinated and non-
vaccinated macaques in several studies [13–15,53]. More
strikingly, we have recently reported an association between
a different high-frequency MHC class I allele, Mamu-B*17, and an
even greater reduction of chronic phase viremia [17]. Mamu-B*17,
but not Mamu-A*01, was also over-represented in a cohort of EC
macaques that maintained chronic phase SIV viremia ,1,000
vRNA copy Eq/ml [17,54].
To test the hypothesis that CD8
+ T cell responses are involved
in the ongoing control of viremia in EC macaques, we recently
treated six ECs (four Mamu-B*17-positive, two Mamu-B*17-
negative) with the monoclonal antibody cM-T807, which
transiently depletes circulating CD8
+ lymphocytes [55]. This
treatment resulted in a brief viral recrudescence in all six ECs,
after which viremia declined back to near pre-depletion levels.
Analysis of the returning wave of CD8
+ T cells showed different
degrees of expansion in epitope-specific populations in each
animal. We noted that the two Mamu-B*17-negative macaques
shared expanding CD8
+ T cell populations that recognized
previously unmapped epitopes in the SIV proteins Vif and Nef.
Here we report minimal optimal sequences for these novel
epitopes and show that they are presented by the MHC class I
molecule Mamu-B*08.
We recently discovered that Mamu-B*08 is strongly associated
with control of SIVmac239 replication [54]. We have extended this
finding, showing that Mamu-B*08 presents at least seven CD8
+ T
cell epitopes derived from SIVmac239. Furthermore, we show that
the sequences of viruses replicating during chronic infection have
substitutions in several Mamu-B*08-restricted epitopes, indicating
that CD8
+ T cells restricted by this molecule exert selective
pressure on the virus at multiple sites. We also report the
construction of Mamu-B*08 tetramers loaded with each of the
newly discovered epitope peptides, enabling us to determine the
chronic-phase immunodominance hierarchy of these responses.
METHODS
Animals and viruses
Indian rhesus macaques (Macaca mulatta) were initially identified as
Mamu-B*08-positive by analysis of MHC class I cDNA libraries.
PCR with sequence-specific primers (PCR-SSP) was used as
previously described [54] for confirmation and to identify
additional Mamu-B*08-positive macaques. Animals were screened
for the presence of nine additional MHC class I alleles (Mamu-
A*01, -A*02, -A*08, -A*11, -B*01, -B*03, -B*04, -B*17, and -
B*29) using PCR-SSP as previously described [56,57].
Animals were infected with the pathogenic molecular clone
SIVmac239 [58] (GenBank accession M33262), with the exception
of macaque r99006, which was infected with an SIVmac239
recombinant bearing escape mutations in three CD8
+ T cell
epitopes [59,60]. Animals’ plasma virus concentrations were
monitored by quantitative PCR as previously described [61,62].
EC macaques r00078, r01064, and r98016 were transiently
depleted of CD8
+ lymphocytes as part of a prior study [55]. These
three ECs and animal r99006 were subsequently rechallenged
intravenously with 100 TCID50 SIVmac239 with no effect on
viremia or the frequency of SIV-specific CD8
+ T cells (Friedrich et
al., unpublished data).
SIV-infected animals were maintained at the National Primate
Research Center (University of Wisconsin-Madison, Madison, WI)
and cared for according to the regulations and guidelines of the
University of Wisconsin Institutional Animal Care and Use
Committee.
Construction of MHC class I cDNA libraries
Total RNA from animals r00078, r01064, and r98016 was isolated
from ,3610
7 cells from B-lymphoblastoid cell lines (BLCL) using
the RNeasy Protect Mini Kit (QIAGEN, Valencia, CA). For each
animal, ,3 mg mRNA was isolated from 150 mg total RNA using
the Oligotex Midi Kit (QIAGEN). One microgram of mRNA
from each animal served as the template for first strand cDNA
synthesis, using the SuperScript plasmid system for cDNA
synthesis and cloning (Invitrogen, Carlsbad, CA) by following
the manufacturer’s instructions. Size-fractionated cDNA contain-
ing SalI and NotI restriction endonuclease cohesive ends was
ligated into the multiple cloning site of pCMV.SPORT6 and used
to transform DH5a chemically competent E. coli (Invitrogen).
Recombinant plasmids containing cDNA were isolated from
,5610
5 ampicillin resistant colonies and purified using the
HiSpeed Plasmid Midi kit (QIAGEN). Five micrograms of plasmid
DNA from each macaque’s library served as the target DNA for
hybridization to a biotinylated oligonucleotide, 59-CGGAGAT-
CAYRCTGACVTGGC-39. The sequence of the capture oligo-
nucleotide was derived from a highly conserved region of the
MHC class I alpha-3 domain. The GeneTrapper cDNA positive
selection system (Invitrogen) was then used to enrich the cDNA
library for MHC class I alleles.
More than 150 MHC class I clones were captured and
sequenced from each library. Sequencing was performed on an
ABI 3730 DNA Analyzer (Applied Biosystems, Foster City, CA).
Full-length sequences of MHC class I cDNAs were obtained by
using four forward and four reverse primers. The forward primers
were: SP6 (59-GGCCTATTTAGGTGACACTATAG-39), C/1+
(59-GCAGATACCTGGAGAACGGG-39), IV (59-GGAACCT-
Mamu-B*08 CTL in SIV ECs
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GTGTCTCTCACG-39). The reverse primers were: T7 (59-
TAATACGACTCACTATAGGG-39), E2 (59-CYCCACCTCC-
TCACATKATGC-39), F1 (59-CCAGGTCAGTGTGATCT-
CCG-39), and G1 (59-ATGTAATCCTTGCCGTCGTA-39).
Sequences were analyzed using CodonCode Aligner version
1.6.3 (CodonCode, Deadham, MA). MHC class I alleles were
considered part of the cDNA library after at least two copies were
verified by sequencing. Novel MHC I sequences were given
GenBank accession numbers: Mamu-A6*0103 (EF602318), re-
ferred to as Mamu-A*15 in Table 1, Mamu-B*31 (EF602319), and
Mamu-B*5102 (EF362450).
Generation and maintenance of SIV-specific CD8
+ T
cell lines
Peptide-specific CD8
+ T cell lines were generated using previously
described methods [62,63]. Briefly, freshly isolated PBMC or
CD8
+ cell-enriched PBMC were used to start CD8
+ T cell lines.
Autologous B-lymphoblastoid cell lines (BLCL) were used as
antigen presenting cells (APCs). BLCL were pulsed with 1 mM
relevant SIV-specific peptide for 1 to 2 hours at 37uC, washed
twice, and irradiated (9,000 rads). BLCL were then mixed with
either whole or CD8
+ cell-enriched PBMC at a ratio of 1:1 in
RPMI 1640 (Cambrex, Walkersville, MD) supplemented with L-
glutamine (Mediatech, Herndon, VA), antibiotic-antimycotic
solution (Mediatech), and 15% fetal bovine serum (FBS; HyClone,
Logan, UT) (R15) with 10 ng/ml of recombinant human
interleukin-7 (Sigma-Aldrich, St. Louis, MO) and incubated for
48 hours. Cells were cultured with R15 containing 100 Units of
interleukin-2/ml (NIH AIDS Research and Reference Reagent
Program, Germantown, MD) (R15-100) every 3 to 5 days
thereafter. The CD8
+ T cell lines were restimulated using
peptide-pulsed, irradiated BLCL every 7 to 14 days. CD8
+ T cell
lines were tested for epitope specificity after .14 days in culture
by either intracellular cytokine staining (ICS) or MHC class I
tetramer assays as previously described [62-64]. MHC class I
tetramers were constructed with minor modifications as previously
described [64,65].
MHC class I transfectants
Transient expression of cloned MHC class I cDNA was achieved
by electroporation of plasmid DNA into the MHC class I deficient
human B-cell line 721.221 [66]. Briefly, 5 mg of plasmid DNA was
added to 5610
6 721.221 cells in 100 ml of Nucleofector
TM
Solution C and electroporated using program G-16 on a Nucleo-
fector I device (Amaxa, Ko ¨ln, Germany). Maximum cell surface
expression occurred four days post-electroporation. The stable
Mamu-B*08 transfectant was created as previously described
[66,67], except for the use of the Nucleofector I device (Amaxa)
according to manufacturer’s protocols.
MHC class I surface expression on stable and transient MHC
class I transfectants was measured by W6/32 antibody surface
staining. Staining was also performed on the 721.221 cells as
a negative control and immortalized macaque B-cell lines (positive
control). Approximately 0.5–1610
5 lymphocyte-gated events were
acquired on a FACSCalibur (BD Biosciences, San Jose, CA) and
analyzed using FlowJo version 8.4.5 (TreeStar, Ashland, OR).
Intracellular cytokine staining (ICS) assay
TNF-a and IFN-c intracellular cytokine staining (ICS) assays were
performed on both freshly isolated PBMC and SIV-specific CD8
+
T cell lines as previously described [55,62,63]. Briefly, each PBMC
ICS test contained ,5610
5 cells, while each CD8
+ T cell line ICS
test contained 2610
5 CD8
+ T cells along with 1610
5 autologous
BLCL. Individual peptides were used at a concentration of 5 mM
or in serial ten-fold dilutions ranging from 5 mM to 5 pM. SIV
peptide pools each contained ten 15-mer peptides overlapping by
eleven amino acids. Approximately 0.5–1610
5 lymphocyte-gated
events were acquired on a FACSCalibur (BD Biosciences) and
analyzed using FlowJo 8.4.5 (TreeStar). All values were normal-
ized by subtracting the background (cytokine-positive events in
negative control samples of PBMC or CD8
+ T cell lines in media
without stimulation).
IFN-c Enzyme-Linked Immunospot (ELISPOT) assay
ELISPOT assays were performed as previously described [62].
Briefly, freshly isolated PBMC were used directly in precoated
ELISpot
PLUS kits (MABTECH Inc, Mariemont, OH) for the
detection of monkey IFN-c according to manufacturer’s protocols.
1610
5 PBMC were used per well and incubated 14–18 hours at
37uCi n5 %C O 2. Peptides were used at 10 mM or in serial ten-
fold dilutions ranging from 10 mM to 10 pM. SIV peptide pools
each contained ten 15-mer peptides overlapping by eleven amino
acids. All tests were performed in either duplicate or triplicate.
Wells were imaged with an AID ELISPOT reader (AID,
Strassberg, Germany), counted by AID EliSpot Reader version
3.2.3, and analyzed as previously described [62,64]. Background
(mean number of spot-forming cells [SFCs] in wells without
peptide stimulation) was subtracted from each well on the plate. A
response was considered positive if the mean number of SFCs
Table 1. Major histocompatibility complex class I profiles of
three CD8
+ cell-depleted EC macaques.
......................................................................
MHC class I MHC class I animal profile
a
r00078 r01064 r98016
Mamu-A alleles A*02 A*02
A*0505
A*0507 A*0507
A*07 A*07
A*08
A*1302 A*1302
A*1303
A*15
b
Mamu-B alleles B*06
c B*06
c B*06
c
B*08 B*08 B*08
B*12
B*17
B*22
B*29012 B*29012
B*30 B*30
B*31
B*5102
B*53 B*53
B*6002
B*64
a)Profile constructed from cDNA libraries of at least 150 sequenced clones.
b)Updated nomenclature in GenBank=A6*0103 (EF602318).
c)Mamu-B*06 has not been detected by 1-D IEF, suggesting that it may not
encode an expressed MHC class I protein [74].
doi:10.1371/journal.pone.0001152.t001
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plus two standard deviations (SD). Assay results are shown as SFCs
per 1610
6 PBMC. Responses ,50 SFCs per 1610
6 PBMC were
not considered positive.
Sequencing of plasma viral RNA
Viral sequencing was performed essentially as previously described
[55,68]. Briefly, viral RNA was extracted from plasma using the
QIAGEN MinElute kit. We used the QIAGEN One Step RT-PCR
kit to amplify overlapping regions ,300–800 nucleotides in length
that spanned the SIVmac239 open reading frames (ORFs) vif, rev,o r
nef. The RT-PCR conditions for all amplicons were as follows: 50uC
for 30 min; 95uC for 15 min; 45 cycles of 94uC for 30 s, 53uCf o r
1 min and 72uC for 150 s; and 68uC for 20 min. Cycling ramp rates
were 2uC per second. The amplified cDNA was purified using the
QIAGEN PCR purification kit. For some extremely low copy
number samples (,100 vRNA copy Eq/ml) PCR products were
directly cloned into the pCRH4-TOPOH vector using the TOPO-
TA Cloning Kit (Invitrogen). Plasmids containing cloned sequences
were purified using the QIAprep Spin Miniprep Kit (QIAGEN).
Both strands of each amplicon were sequenced on a 3730 DNA
Analyzer (Applied Biosystems). Sequences were assembled using
Aligner version 1.6.3 (CodonCode). DNA sequences were concep-
tually translated and aligned to wild type SIVmac239 in MacVector
9.0 trial version (Accelrys, Burlington, MA).
Statistical analysis of viral variation
The number of synonymous substitutions per synonymous site (dS)
and the number of nonsynonymous substitutions per nonsynon-
ymous site (dN) between the viral sequence obtained from each
animal’s circulating virus and the inoculum sequence (SIVmac239)
were estimated using the method of Nei and Gojobori [69], and
the results were analyzed as previously described [68,70]. In the
case of ambiguous nucleotides, we assumed equal occurrences of
the possible nucleotides in the viral population in any given
monkey. Note that, since the virus evolved independently in each
monkey, comparisons of viral sequences with the inoculum are
both statistically and phylogenetically independent [71].
RESULTS
Mamu-B*17-negative ECs share robust responses to
novel epitopes derived from Vif and Nef.
While the majority of SIV ECs express Mamu-B*17 [17], several do
not. In an attempt to define the immune correlates of control, we
depleted CD8
+ cells in vivo from four Mamu-B*17-positive and two
Mamu-B*17-negative ECs [55]. In this transient CD8
+ cell depletion
experiment, particular virus-specific CD8
+ T cells repopulating the
periphery expanded above baseline frequencies. The set of epitopes
recognized by expanding populations was different in each animal,
butineachcasepreviouslysubdominantpopulationsshowedamuch
greater relative expansion than dominant ones. We hypothesized
that these expanding CD8
+ T cell populations played an important
role in the re-assertion of control over SIV replication.
Expanding CD8
+ T cell populations in the four Mamu-B*17-
positive ECs after depletion targeted epitopes in Vif and Nef [55].
Interestingly, expanding populations in the two Mamu-B*17-
negative ECs, r00078 and r01064, also responded to peptides
derived from these proteins (Fig. 1A). Indeed, both Mamu-B*17-
negative ECs had large populations of CD8
+ lymphocytes that
recognized the same pool of ten Vif 15-mer peptides, Vif E
(SIVmac239 Vif residues 161-214). To determine whether the
animals might be recognizing the same epitope, we mapped the
minimal optimal epitope recognized by both animals. First, we
deconvoluted the 15-mer peptide pool, testing the ability of each
individual 15-mer to stimulate IFN-c secretion by the animals’
PBMC in ICS assays. These experiments showed that the response
to the pool was recapitulated by stimulation with either of two
individual 15-mers (Fig. 1B). Since the responses to each 15-mer
were very similar in magnitude for both animals, we reasoned that
the minimal optimal epitope was contained within the region of
overlap for the two peptides. IFN-c ELISPOT assays using
dilutions of candidate minimal optimal peptides showed the
epitope recognized by each animal to be an 8-mer, RRDNRRGL,
Vif172–179RL8 (Fig. 1C).
We also noted a strong response to an unidentified epitope in
a third EC, r98016. More than 3% of this animal’s returning
CD8
+ lymphocytes responded to a pool of Nef-derived 15-mers,
Nef D (SIVmac239 Nef residues 125–179) (Fig. 2A). This peptide
pool contains previously described dominant epitopes bound by
Mamu-A*02 (Nef159–167YY9) [63,72] and Mamu-B*17 (Nef165–
173IW9) [16,67,73]. Surprisingly, although r98016 expressed both
Mamu-A*02 and B*17, only ,0.1% of its CD8
+ lymphocytes
recognized the Nef165–173IW9 peptide, while responses to Nef159–
167YY9 were undetectable (Fig. 2A). The Mamu-A*02-negative,
Mamu-B*17-negative EC r00078 also made a strong response to
the same Nef pool after CD8
+ cell depletion (0.26% CD8
+ IFN-c
+,
Fig. 1A and data not shown). We therefore hypothesized that these
animals made a CD8
+ T cell response to a novel epitope in Nef,
which was not presented by either Mamu-A*02 or -B*17. To test
this hypothesis, we first deconvoluted the response to Nef pool D
in r98016 using ICS for IFN-c and TNF-a. The strongest response
to an individual peptide was stimulated by a single 15-mer, Nef137–
151 (Fig. 2B). No 8-mer or 9-mer Nef peptide in this region elicited
a similarly strong response (data not shown). To define the
minimal optimal epitope we then tested the ability of serial ten-fold
dilutions of larger candidate peptides (ten to twelve amino acids in
length) to stimulate IFN-c and TNF-a secretion in ICS assays
using Nef-specific CD8
+ T cell lines from animal r98016 (Fig. 2C).
Although the 10-mer, 11-mer, and 12-mer all showed similar
functional avidity, we defined the 10-mer as the minimal optimal,
since it was the shortest peptide to stimulate the maximal response.
The sequence of this peptide was RRHRILDIYL, Nef137–
146RL10. IFN-c ELISPOT assays using PBMC gave similar
results, further suggesting that Nef137–146RL10 was the minimal
optimal epitope recognized by r98016 (data not shown). PBMC
from animals r00078 and r01064 also recognized overlapping 15-
mer peptides containing this 10-mer sequence (see below),
suggesting that all three ECs responded to this same epitope.
MHC class I tetramer refolding subsequently confirmed that
Nef137–146RL10 is the minimal optimal epitope bound by Mamu-
B*08 (data not shown).
CD8
+ T cells from SIV EC macaques recognized novel
Mamu-B*08-restricted epitopes
It appeared that all three ECs recognized the same novel Nef137–
146RL10 epitope, RRHRILDIYL, while at least two animals,
r00078 and r01064, recognized the novel Vif172–179RL8 epitope
RRDNRRGL. Both these peptides had a diarginine motif at their
N-termini and a leucine residue at their C-termini. Furthermore,
BLCL derived from all three animals could present peptides to
Vif172–179RL8-specific CD8
+ T cell lines from animals r00078 and
r01064 and also to Nef137–146RL10-specific CD8
+ T cell lines
generated from r98016 (data not shown). We therefore hypoth-
esized that the novel epitopes were bound by the same, as yet
unidentified, MHC class I molecule.
Mamu-B*08 CTL in SIV ECs
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+ response directed against Vif that expanded in two CD8
+ cell-depleted EC macaques,
r00078 and r01064. MHC class I alleles detected by PCR-SSP are listed for each animal. A) Unknown CD8
+ responses from ex vivo ICS assays using SIV
peptide pools performed one month prior to (white bars) and four weeks after (black bars) CD8
+ cell depletion. Responses to 15-mer pools that did
not contain previously identified minimal optimal epitope sequences [64,73,82] are summed for each protein. Of particular interest was an unknown
SIV-specific CD8
+ response directed against Vif, which expanded in two Mamu-B*17-negative ECs r00078 and r01064. B) Ex vivo ICS deconvolution of
peptide pool Vif E (positions 161–214) using r00078 PBMC demonstrated that the novel CD8
+ epitope was located within two overlapping 15-mers in
Vif (positions 165–183). C) Ex vivo IFN-c ELISPOT using peptide dilutions in r00078 fine-mapped the novel CD8
+ epitope to an 8-mer at positions 172–
179 in Vif (RRDNRRGL). Mean values from triplicate wells were calculated for each peptide test.
doi:10.1371/journal.pone.0001152.g001
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+celldepletionstudyhadbeenscreenedforthe
presence of nine MHC class I alleles by sequence-specific PCR
(PCR-SSP). Animals r00078, r01064, and r98016 did not share an
allele detected in this screen (Figs. 1 and 2). PCR-SSP is useful as
a high-throughput screen for the presence or absence of particular
alleles of interest, but does not give a complete MHC class I
genotype. In order to determine the full complement of MHC class I
genes ineachofthe three ECs,weprepared cDNAlibrariesofMHC
class I sequences from each animal. We sequenced at least 150
individually cloned cDNAs from these libraries for each EC. This
number of clones is typically sufficient to identify the majority, if not
all, of the MHC class I alleles expressed in an animal. Screening of
the MHC class I cDNA libraries revealed two MHC class I alleles
shared by all three ECs: Mamu-B*06 and Mamu-B*08 (Table 1). We
had previously determined that Mamu-B*08 encodes a protein
detectable by one-dimensional isoelectric focusing (1-D IEF), while
Mamu-B*06 does not [74]. It was therefore likely that the restricting
element for the two novel epitopes was encoded by Mamu-B*08.
Figure 2. Identification and mapping of a novel CD8
+ response directed against Nef that expanded in the CD8
+ cell-depleted EC macaque
r98016. MHC class I alleles detected by PCR-SSP are listed for r98016. A) Unknown CD8
+ responses from ex vivo ICS assays using SIV peptide pools
performed one month prior to (white bars) and four weeks after (black bars) CD8
+ cell depletion. Responses to 15-mer pools that did not contain
previously identified minimal optimal epitope sequences [i.e., Nef159–167YY9 and Nef165–173IW9] [64,73,82] are summed for each protein. Of particular
interest was an unknown SIV-specific CD8
+ response directed against Nef, which expanded in Mamu-B*17-positive EC r98016. B) Ex vivo ICS
deconvolution of peptide pool Nef D (positions 125–179) using r98016 PBMC revealed that the novel CD8
+ epitope was located within two
overlapping 15-mers in Nef (positions 133–151). C) ICS results using peptide dilutions with a Nef-specific CD8
+ T cell line from r98016 fine-mapped
the novel CD8
+ epitope to a 10-mer at positions 137–146 in Nef (RRHRILDIYL).
doi:10.1371/journal.pone.0001152.g002
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PLoS ONE | www.plosone.org 6 November 2007 | Issue 11 | e1152To test the hypothesis that Mamu-B*08 presented the novel
epitopes, we next generated CD8
+ T cell lines from the three ECs
using 15-mer peptides containing the Vif or Nef epitopes. We also
stably transfected 721.221 cells [66,67] with expression constructs
for Mamu-B*08 or Mamu-A*01. 721.221 is a human cell line that
does not express classical MHC class I molecules, so the only
MHC class I molecules on the surface of the transfectants were the
products of the transfected constructs. We then asked whether
Mamu-B*08 transfectants could present exogenous peptides and
elicit cytokine responses detectable in ICS assays. Indeed, CD8
+ T
cell lines responded at least as strongly to Mamu-B*08-transfectant
cells as they did to autologous B-lymphoblastoid cell lines (BLCL)
pulsed with either the Vif peptides (Fig. 3A) or the Nef peptides
(Fig. 3B). The CD8
+ T cell lines did not respond to mismatched
Mamu-A*01 transfectants pulsed with the same peptides (Fig. 3A
and 3B) or to peptide-pulsed 721.221 cells (data not shown). Taken
together, these data indicate that Mamu-B*08 presents the novel
epitopes derived from SIV Vif and Nef.
Identification of five more Mamu-B*08-restricted
CD8
+ T cell epitopes derived from SIVmac239
The Nef epitope we identified, Nef137–146RL10 (RRHRILDIYL),
overlapped with a previously identified epitope, Nef136–146AL11
(ARRHRILDIYL), which is restricted by Mamu-B*03 [22,67].
Therefore, we compared the amino acid sequences of these two
MHC class I molecules to determine whether we could predict
a peptide binding motif for Mamu-B*08 extrapolated from the
known motif of Mamu-B*03 [75]. Mamu-B*03 and Mamu-B*08
are almost identical in amino acid sequence [74]. There are only
two amino acid differences between these molecules in regions that
influence peptide binding and antigen recognition [76,77]. Both
differences reside in the alpha-1 domain (exon 2). Thus, based on
these overall structural similarities, analysis of the B and F pockets
of Mamu-B*08 in comparison with well-characterized HLA and
Mamu specificities, and the sequences of known Mamu-B*03
[22,67] and the identified Mamu-B*08 epitopes (Figs. 1 and 2),
a preliminary Mamu-B*08 peptide binding motif was derived.
This preliminary motif specifies the presence of arginine (R) in
position 2 (P2) and the aliphatic hydrophobic residues leucine (L),
isoleucine (I), or valine (V) at the C-terminus.
We then used the preliminary binding motif to scan SIVmac239
Vif, Nef, and Rev for additional potential Mamu-B*08-restricted
epitopes. We focused in particular on these regions because CD8
+
T cell populations recognizing these three proteins expanded in
r00078, r01064, and r98016 after CD8
+ cell depletion (Fig. 4A).
We used ELISPOT assays to test the ability of 15-mer peptides
Figure 3. Mamu-B*08 restricts both of the novel SIV-specific CD8
+ T
cell responses observed in the CD8
+ cell-depleted EC macaques.
721.221 cells, which do not express endogenous classical MHC class I
molecules, were stably transfected with Mamu-B*08 or Mamu-A*01 and
pulsed with the appropriate peptides. Peptide-pulsed cells were used in
ICS assays with peptide-specific CD8
+ T cell lines. CD8
+ T cell lines raised
against 15-mers derived from A) Vif (positions 165–183) from animal
r00078 and B) Nef (positions 133–151) from animal r98016 were
stimulated by the Mamu-B*08 stable transfectants pulsed with the
relevant peptides. The cytokine reactivity was comparable to levels
elicited when autologous BLCL were used as APCs (positive control). No
peptide stimulation was observed when using the Mamu-A*01 stable
transfectants as APCs (negative control). Negative controls without
peptide in the presence of APCs also gave negligible cell stimulation.
Percentages over each FACS dot plot signify the maximal cytokine
response (total of IFN-c
+ cells, TNF-a
+ cells, and IFN-c
+ TNF-a
+ cells).
doi:10.1371/journal.pone.0001152.g003
Table 2. Summary of seven novel SIV-derived epitopes
restricted by Mamu-B*08 that were identified in four EC
macaques.
......................................................................
Protein Amino Acid Positions Length Short Name Sequence
Vif 123–131 9 RL9 RRAIRGEQL
Vif 172–179 8 RL8 RRDNRRGL
Rev 12–20 9 KL9 KRLRLIHLL
Rev 44–51 8 RL8 RRRWQQLL
Nef 8–16 9 RL9 RRSRPSGDL
Nef 137–146 10 RL10 RRHRILDIYL
Nef 246–254 9 RL9 RRLTARGLL
doi:10.1371/journal.pone.0001152.t002
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PLoS ONE | www.plosone.org 7 November 2007 | Issue 11 | e1152containing sequences that fit the motif to stimulate IFN-c release
by PBMC from these three ECs.
We also determined that an additional animal in the EC cohort,
r99006, expressed Mamu-B*08, so this animal was included in
further analyses. r99006 was challenged with a recombinant virus
bearing escape mutations in Mamu-A*01- and Mamu-B*17-
restricted CD8
+ T cell epitopes as part of a prior study [59,60].
This animal has controlled viremia to ,1,000 vRNA copy Eq/ml
for over four years post-SIV infection and was not part of the
CD8
+ cell depletion study. Responses to four peptide pools
containing putative Mamu-B*08-restricted epitopes were weakly
detectable in ICS assays of r99006 PBMC conducted 30 weeks
post-infection (Fig. 4A).
Testing PBMC from all four ECs, we identified another five
putative Mamu-B*08-restricted CD8
+ T cell epitopes derived from
Vif, Nef, and Rev (Fig. 4B). TNF-a and IFN-c ICS assays using
Mamu-B*08 and Mamu-A*01 transfectants confirmed that each of
these epitopes was presented by Mamu-B*08 (data not shown). For
each Mamu-B*08-restricted response detected by 15-mers, we
selected candidate peptides within the 15-mers to define the
minimal optimal epitopes. These candidate peptides were chosen
on the basis of the preliminary motif and tested in serial dilutions
in TNF-a and IFN-c ICS assays with peptide-specific CD8
+ T cell
lines as described above for Vif172–179RL8 and Nef137–146RL10
(data not shown). All seven minimal optimal epitopes had an R
residue at P2 and L at the C-terminus, in agreement with the
putative Mamu-B*08 binding motif (Table 2).
Surprisingly, a majority of the novel Mamu-B*08-restricted
CD8
+ T cell responses were detected in at least two ECs over 1.5
years after initial infection with SIVmac239 (Fig. 4B). Among
these responses, populations recognizing the Nef137–146RL10
epitope appeared dominant or co-dominant in three of four ECs
tested. The exception to this pattern was animal r01064, whose
Mamu-B*08-restricted response appeared to be dominated by cells
responding to an epitope in the C-terminus of Rev, Rev44–51RL8.
However, the overlapping Rev 15-mers tested contain not only
a Mamu-B*08-restricted CD8
+ T cell epitope but also a CD8
+ T
cell epitope of unknown restriction, which may contribute to the
strength of immune responses elicited by this peptide (data not
shown). Further experiments suggested that the strong response to
the Rev 15-mer we observed in r01064 is due to cells that
recognize this unknown epitope (see below).
Staining PBMC with Mamu-B*08 tetrameric
complexes reveals the immunodominance hierarchy
of Mamu-B*08-restricted CD8
+ T cell responses
Having defined seven minimal optimal epitopes bound by Mamu-
B*08, we next produced tetrameric complexes of Mamu-B*08
loaded with each of these epitopes. The PCR-SSP-based screen for
Mamu-B*08 we developed allowed us to test for the presence of this
allele in PBMC from 192 SIVmac239-infected rhesus macaques
[54]. Seven animals from this cohort expressed Mamu-B*08: four
of these were the previously identified ECs, and three were
animals that progressed to AIDS [17,54].
We used the set of Mamu-B*08 tetramers to measure the
Mamu-B*08-restricted CD8
+ T cell response in archived chronic-
phase PBMC from six of these seven SIV-infected macaques. For
each epitope, there were detectable tetramer-binding populations
of CD8
+ T cells in at least two animals (Table 3). In most
instances, the frequency of SIV-specific CD8
+ T cells against each
of the seven novel Mamu-B*08-restricted epitopes was higher in
the four EC macaques than the two progressors. Populations
recognizing Nef137–146RL10 were dominant in one of the six
macaques (r99006), and co-dominant in three more animals with
Vif172–179RL8 (r96104) and with Rev12–20KL9 (r98016, r96113).
Nef8–16RL9-specific cells were dominant or co-dominant in the
remaining two animals (r00078 and r01064). The Nef245–254RL9
was co-dominant with the Nef8–16RL9-specific in r00078.
The high frequency populations detected by Mamu-B*08 Nef137-
146RL10 tetramers also confirmed that responses we detected by
IFN-c ELISPOT in four Mamu-B*08-positive ECs were directed
against this Mamu-B*08-restricted epitope (Fig. 4B). Indeed, there
was general concordance between the immunodominance hierarchy
detected by ELISPOT and that measured by tetramers with one
exception. In animal r01064 using the Rev44–53RL8 tetramer, we
did not detect a CD8
+ T cell response (Table 3), although 15-mer
peptides containing this sequence elicited the dominant response in
ELISPOT assays (Fig. 4B). This result further suggests that the
strong response detected in ELISPOT is due to a population that
recognizes an epitope not presented by Mamu-B*08.
Mamu-B*08-restricted CD8
+ T cells select for viral
variation in several SIVmac239 epitopes
To determine whether viral variation in CD8
+ T cell epitopes
could be associated with expression of Mamu-B*08, we first
sequenced vif, rev, and nef ORFs in virus isolated from plasma of
chronically infected Mamu-B*08-positive controllers and progres-
sors. We compared the predicted amino acid sequences of the
epitope regions and full-length proteins to sequences previously
obtained at the time of necropsy from 34 Mamu-B*08-negative
MHC-defined macaques infected with SIVmac239 [68]. Strikingly,
amino acid substitutions accumulated in each of the seven Mamu-
B*08-restricted epitopes we identified in at least two Mamu-B*08-
positive macaques (Fig. 5). The substitutions were rarely in
residues likely to be crucial for binding to the Mamu-B*08
molecule, P2 or the C-terminus. One exception to this pattern was
Vif172–179RL8, in which substitutions affected either P2 or the C-
terminus in each animal with epitope mutations. Peptides with P2
glycine (G)-for-arginine (R) substitutions were not recognized by
Vif172–179RL8-specific CD8
+ T cell lines in ICS assays, supporting
the conclusion that these mutations confer escape from Mamu-
B*08-restricted CD8
+ T cell responses (data not shown).
In order to examine the effects of selection pressure on Mamu-
B*08-restricted epitope sequences more closely, we compared the
numbers of nonsynonymous (dN) and synonymous (dS) substitutions
persitewithinepitope-coding regions of vif, rev,an dnefwith dN and dS
for the entire ORFs. This analysis showed that dN was significantly
elevated in regions encoding Mamu-B*08-restricted epitopes in
animals expressing this molecule (P,0.001, Table 4). Furthermore,
dN within the epitope regions was greater in Mamu-B*08-positive
than in Mamu-B*08-negative animals (P,0.001), while dS was not
significantly different between the groups (Table 4). These results
suggest that regions encoding Mamu-B*08-restricted CD8
+ Tc e l l
epitopes are under selective pressure only in the presence of Mamu-
B*08, and thus the variation we detect in Mamu-B*08-restricted
epitopes is indeed selected by CD8
+ T cell responses.
In one case, substitutions associated with Mamu-B*08 expression
occurred not in the epitope sequence, but immediately N-terminal
to it. Virus from each of the Mamu-B*08-positive macaques tested
had a substitution at Nef residue 136, which is alanine (A) in
SIVmac239. The variant sequence encoded a proline (P) at this
position (A136P) in five of six animals (Fig. 5). The dN/dS ratio was
significantly elevated at this position only in Mamu-B*08-positive
animals, indicating strong selection pressure favoring this mutation
only in the presence of Mamu-B*08 (data not shown). Since Nef
residue 136 is not within the minimal optimal epitope bound by
Mamu-B*08 CTL in SIV ECs
PLoS ONE | www.plosone.org 8 November 2007 | Issue 11 | e1152Figure 4. Expansion and persistence of seven SIV-specific Mamu-B*08-restricted CD8
+ lymphocyte responses in four EC macaques. MHC class I
alleles detected by PCR-SSP are listed for each animal. A) Unknown CD8
+ responses from ex vivo ICS assays using SIV peptide pools (containing ten
15-mers overlapping by eleven amino acids) performed one month prior to and four weeks after CD8
+ cell depletion. Chronic phase (thirty weeks
post-infection) ex vivo ICS data is also shown for responses in r99006 to the seven SIV 15-mer peptide pools that contain the novel CD8
+ T cell
epitopes. Grayed responses increased .0.1% after CD8
+ cell depletion (r00078, r01064, and r98016). B) Ex vivo IFN-c ELISPOT using one or two
overlapping 15-mers containing the minimal optimal Mamu-B*08-restricted SIV-specific epitopes (or the minimal optimal peptide alone, in the case
of Vif172–179RL8) demonstrated that these CD8
+ responses persist approximately six months post-CD8
+ cell depletion in ECs r00078, r01064, and
r98016. CD8
+ cell responses persist in r99006 at ,3.5 years post-SIV infection. Mean values and SD from triplicate wells were calculated for each
ELISPOT assay. Background (the mean of wells without peptide) levels were subtracted from each well. Mean responses ,50 SFC per 1610
6 cells
were not considered positive because these counts were not significantly above background.
doi:10.1371/journal.pone.0001152.g004
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decreasing the availability of minimal optimal epitopes to Mamu-
B*08 molecules. Indeed, a similar A to P substitution immediately
N-terminal to the epitope is known to inhibit processing of an
HLA-B57-restricted peptide in HIV Gag [78]. At position 136, the
A to valine (V) substitution found in EC r98016 is much more
conservative and may not alter processing of the epitope. We also
detected a substitution one amino acid N-terminal of the minimal
optimal Nef246–254RL9 epitope in progressor r96113 (Fig. 5). This
was a conservative lysine (K)-for-R substitution, so the impact of
this change on peptide processing may be small. This same
substitution was also found in two of 33 Mamu-B*08-negative
macaques, and relative rates of nonsynonymous and synonymous
substitutions were not significantly different in this epitope region
in Mamu-B*08-positive and Mamu-B*08-negative animals (data not
shown). These data suggest that the R245K substitution is not
selected for by Mamu-B*08-restricted CD8
+ T cells.
To clarify whether substitutions in Mamu-B*08-restricted
epitopes might affect the ability of Mamu-B*08-positive animals
to control SIVmac239 infection, we next determined epitope
sequences of viruses circulating in Mamu-B*08-positive ECs before
and after CD8
+ cell depletion, when SIV replication was
effectively controlled (Fig. 6). We compared these sequences to
those present in virus replicating in the absence of CD8
+ T cell
selection during the CD8
+ cell depletion phase, which we had
determined previously [55]. To our surprise, variation in several
Mamu-B*08-restricted epitopes was detectable in ECs r98016 and
r00078 even before CD8
+ cell depletion, when viremia had been
successfully controlled to ,1,000 vRNA copy Eq/ml for up to two
years (Fig. 6). Repeated attempts to amplify viral cDNA from
r01064 pre-depletion plasma samples were unsuccessful, likely due
to the extremely low concentrations of vRNA in this animal.
Viral variation was detectable prior to depletion in five of seven
identified Mamu-B*08-restricted epitopes in r00078, and in four of
six epitopes for which sequence was available in r98016.
Mutations present before depletion were still detectable during
the peak of virus replication, with three exceptions. Mutations
detected in animal r00078 Nef246–254RL9 were not present at
peak, although at least one of these mutations, encoding R246K,
was detected in the two other ECs’ peak virus (Fig. 6). Also in
animal r00078, a leucine (L)-for-P substitution was also detected at
position five of Nef8–16RL9 before CD8
+ cell depletion, but not in
the virus replicating in the absence of CD8
+ cells. This same
substitution reappeared in virus populations isolated at later
timepoints, after the return of CD8
+ cells. Virus from animal
r01064harboredmutationsinthesamecodon,resultinginadifferent
amino acid substitution (P to glutamine, Q). This change was
similarlyabsent from virusreplicationduring CD8
+celldepletion.In
addition, a pre-depletion site of mixed-base heterogeneity N-
terminal to Nef137–146RL10 in r98016, encoding A and glutamic
acid (E), was fully wild type at the peak of virus replication. In
contrast, r00078’s virus at position 136 had an A-to-P mutation
before, during and after CD8
+ cell depletion. These results suggest
that commonly detected mutations within these Mamu-B*08-
restricted epitopes do not likely exact a heavy cost to viral fitness.
The two Mamu-B*08-positive, Mamu-B*17-negative ECs even-
tually lost control of viremia, with plasma virus concentrations
increasing beyond 1,000 vRNA copy Eq/ml beginning ,150 days
after CD8
+ cell depletion treatment. Animal r00078’s viremia
stabilized at a new plateau level of ,10,000 vRNA copy Eq/ml by
day 300 after depletion, but r01064 had steadily increasing
viremia and was sacrificed at day 542 post-depletion with a plasma
virus concentration of 1610
6 vRNA copy Eq/ml (data not shown).
We sequenced plasma virus at two timepoints following this virus
breakthrough in both animals to determine whether variation in
Mamu-B*08 epitopes could account for their loss of control.
Although the patterns of variation were different in each animal,
post-breakthrough virus had substitutions that had not been
detected immediately after CD8
+ cell depletion (Fig. 6). Although
we cannot yet determine which substitutions in particular Mamu-
B*08-restricted CD8
+ T cell epitopes can be correlated with loss of
effective viremia control, we were surprised to find that Mamu-
B*08-restricted CD8
+ T cell responses appeared to select for viral
variation in all identified epitopes in the majority of animals.
DISCUSSION
In a recent study aimed at identifying correlates of EC of SIV
replication, we transiently depleted CD8
+ cells from the periphery
in six macaque ECs [55]. Four of these animals expressed Mamu-
B*17, which we had previously shown to be associated with
a reduction in chronic phase viremia in a large cohort of
SIVmac239-infected macaques [17]. In that study, we found that
particular epitope-specific populations of CD8
+ T cells expanded
dramatically as CD8
+ cells repopulated the periphery and control of
virus replication was re-established. In the Mamu-B*17-positive
Table 3. Comparison of CD8
+ T cell responses detected by MHC class I tetramers folded with the seven Mamu-B*08-restricted SIV-
specific epitopes reveals the chronic phase immunodominance hierarchy.
..................................................................................................................................................
Animal # Timepoint % CD3
+ CD8
+ tetramer
+ gated lymphocytes
a
Vif (123–131)
RL9
Vif (172–179)
RL8
Rev (12–20)
KL9
Rev (44–51)
RL8
Nef (8–16)
RL9
Nef (137–146)
RL10
Nef (246–254)
RL9
r00078 ,6 months post-CD8
+ cell
depletion
0.064 0.9 0.23 0.54 1.13 0.87 1.16
r01064 ,6 months post-CD8
+ cell
depletion
0.24 1.07 1.58 - 2.5 0.39 0.87
r98016 ,6 months post-CD8
+ cell
depletion
0.46 0.05 1.34 - 0.041 1.06 0.059
r99006 ,3.5 years post-SIV infection 0.38 0.26 0.18 - - 1.8 0.13
r96104 TOD (60 wks post-SIV infection) - 0.1 - - 0.04 0.088 0.033
r96113 TOD (75 wks post-SIV infection) 0.034 0.055 0.21 0.069 - 0.2 0.023
# of responders 5 6 5 2 4 6 6
a)Tests in which the frequency of tetramer-binding cells was ,0.02% are displayed as a dash (–).
doi:10.1371/journal.pone.0001152.t003
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PLoS ONE | www.plosone.org 10 November 2007 | Issue 11 | e1152animals these expanding populations frequently targeted previously
described Mamu-B*17-restricted epitopes in Vif and Nef. To our
surprise, the Mamu-B*17-negative animals in that study also had
expanding populations of CD8
+ T cells that targeted Vif and Nef
(Figs. 1 and 2). Because these populations showed a substantial
expansion as control of SIV replication was re-asserted, we speculate
that they played an important role in this control.
Here we show that these expanding CD8
+ T cell populations in
the Mamu-B*17-negative macaques recognized novel epitopes
bound by the MHC class I molecule Mamu-B*08 (Fig. 3). Indeed,
Mamu-B*08 presents at least seven epitopes derived from
SIVmac239 to CD8
+ T cells (Table 2) and is expressed in three of
the six ECs in our CD8
+ cell depletion study, including both Mamu-
B*17-negative ECs. We recently reported that Mamu-B*08 was
enriched in a cohort of EC macaques and is associated with reduced
chronic phase viremia in SIVmac239-infected rhesus macaques [54],
further indicating that Mamu-B*08-restricted CD8
+ Tc e l lr e s p o n s e s
play an important role in controlling SIV replication. Using cytokine
secretion assays and synthesizing Mamu-B*08 tetramers, we found
strong responses tothe newly defined epitopes inchronically infected
ECs, even when viremia was low. Among the newly identified
epitopes were two derived from SIVmac239 Rev, Rev12-20KL9 and
Rev44-51RL8. These are the first MHC class I minimal optimal
epitopes described in SIV Rev.
Cytokine secretion assays and MHC class I tetramer stains also
allowed us to identify immunodominance hierarchies among
Mamu-B*08-restricted CD8
+ T cell populations (Fig. 4 and
Table 3). Nef137–146RL10-specific CD8
+ T cells were dominant
or co-dominant as detected by MHC class I tetramers in four of six
Mamu-B*08-positive animals in the chronic phase of SIV infection.
Strong IFN-c responses to Nef137–146RL10-containing peptides
were also detected in all four Mamu-B*08-positive ECs. CD8
+ T
Figure 5. Amino acid variation in novel epitope sequences is associated with expression of Mamu-B*08. Viral RNA was isolated from cell-free
plasma and directly sequenced. Samples were taken from the time of necropsy for four Mamu-B*08-positive macaques that were sacrificed with
progressive SIVmac239 infection (time of necropsy indicated for each animal): r01064 (77 weeks post-CD8
+ cell depletion, 129 weeks post-SIV
infection), 99C093 (127 weeks post-SIV infection), r96104 (60 weeks post-SIV infection), and r96113 (75 weeks post-SIV infection). Virus was sampled
from Mamu-B*08-positive EC r00078 78 weeks post-CD8
+ cell depletion (161 weeks post-infection) after viral breakthrough. Virus was sampled from
Mamu-B*08-positive EC r98016 during a transient increase in SIV replication at 48 weeks post-CD8
+ cell depletion (164 weeks post-infection) during
which virus load rose to ,9,000 vRNA copy Eq/ml before returning to ,1,000 copy Eq/ml. Viral sequences from Mamu-B*08-positive animals were
compared to sequences obtained at the time of necropsy from 34 Mamu-B*08-negative progressors [68]. The frequency of each sequence detected in
these 34 animals is listed in parentheses except for Nef 245–254 where sequences were available from 33 of the 34 animals. Amino acid residues
immediately N-terminal to two Nef epitopes are listed and denoted with a space. Those amino acids identical to the wild-type sequence are shown as
dots. Complete amino acid replacements are shown in uppercase; sites of mixed-base heterogeneity are shown in lowercase.
doi:10.1371/journal.pone.0001152.g005
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PLoS ONE | www.plosone.org 11 November 2007 | Issue 11 | e1152cell populations responding to Rev or Vif epitopes were co-
dominant with or subdominant to these Nef137-146RL10-specific
populations in the three ECs.
Sequencing of vif, rev, and nef ORFs revealed that Mamu-B*08-
restricted CD8
+ T cells exert selective pressure on a surprisingly
broad scale. All seven epitopes we identified had substitutions in at
least two of seven chronically SIV-infected Mamu-B*08-positive
animals (Fig. 5). Substitutions within the dominant Nef137–
146RL10 epitope sequence were infrequent in these animals, but
a mutation one codon upstream of the epitope (encoding A136P)
occurred in six of seven Mamu-B*08-positive animals. A study of
HIV-infected patients showed that viruses bearing a similar
alanine-to-proline substitution immediately N-terminal of an
HLA-B57-restricted Gag epitope were not recognized by epi-
tope-specific CTL [78]. In that case, the A-to-P mutation altered
processing of the epitope peptide, decreasing its availability for
loading onto HLA-B57. It is possible that the A136P substitutions
we observed in Nef similarly alter processing of the Mamu-B*08-
restricted epitope peptide. We detected evidence for positive
selection pressure on Mamu-B*08-restricted CD8
+ T cell epitopes
associated with expression of Mamu-B*08 (Table 4). Therefore, it is
likely that these substitutions represent viral escape from Mamu-
B*08-restricted CD8
+ T cell responses. Viral escape in particular
CD8
+ T cell epitopes has previously been correlated with a loss of
effective immune containment of viremia in HLA-B27-positive
humans and Mamu-A*01-positive macaques [21,24,49–51]. In our
study, it was difficult to correlate particular epitope substitutions
with the eventual loss of control of viral replication in two CD8
+
cell-depleted Mamu-B*08-positive ECs (Fig. 6).
It is thought that individuals with ‘‘elite’’ control of HIV
infection provide an important and all-too-rare example of
successful host responses to the virus. Although these individuals
have been studied for at least ten years, the mechanisms of control
have been extremely difficult to define. Expression of particular
MHC class I alleles, particularly HLA-B27 and -B57, has been
associated with elite control of HIV infection [7–12]. It seems
reasonable to infer from this association that certain HLA-B27-
and HLA-B57-restricted epitope-specific CD8
+ T cells are
particularly effective at controlling virus replication. But so far,
with the possible exception of the HLA-B27-restricted epitope
Gag263-272KK10, no candidate ‘‘controller’’ responses have been
identified. MHC class I alleles may exert their protective effects
through additional, as yet unknown, means.
Animal models of MHC class I-associated elite control of
immunodeficiency virus replication could therefore offer a valuable
tool for studying the mechanisms of control. We have previously
shownthat Mamu-B*17 is over-represented ina cohortofSIVmac239
ECs [17]. Recently, we discovered that Mamu-B*08 expression is
associated with a reduction in chronic phase viremia of a similar
magnitude to that seen for Mamu-B*17 [54]. Interestingly, the
peptide binding motif of Mamu-B*17 is broadly similar to that of
HLA-B57. Although Mamu-B*17 seems to tolerate a wider array of
residues at P2, both molecules exhibit a preference for W, F, or Y at
the C-terminus [73,79,80]. At the same time, a preliminary binding
motif for Mamu-B*08, defined on the basis of structural analyses, is
similar to that defined for HLA-B27 [74,75,79,80]. All seven Mamu-
B*08-restricted CD8
+ T cell epitopes we identified contained R at
position 2 and L at the C-terminus, which also fits the HLA-B27
motif. Indeed, a recent study has provided evidence that this P2
requirement for R, a long, basic residue, may result in some unusual
peptide binding and presentation characteristics for HLA-B27.
Peptides with a dibasic N-terminal motif were relatively resistant to
degradation by cytosolic aminopeptidases, resulting in an over-
representation of peptides with the N-terminal motif KR or RR in
the HLA-B27 peptidome [81]. The authors of that study suggested
that because HLA-B27 ‘‘selects’’ ligands that are particularly stable
in the cytosol. It therefore may require fewer molecules of viral
peptides than other HLA class I molecules to trigger a response from
CD8
+ T cells. This might help explain the apparent effectiveness of
HLA-B27-restricted CD8
+ Tc e l lr e s p o n s e sa g a i n s tH I V .S i n c e
Mamu-B*08 shares the peptide-binding characteristics of HLA-B27,
it may similarly restrict CD8
+ T cells capable of recognizing infected
cells even when cytosolic virus-derived peptide concentrations are
low, for example immediately after infection, or in latent infection.
As the HIV pandemic progresses, so does the urgent need for an
AIDS vaccine. Although there is broad agreement that CD8
+ T
cell responses will be an important component of vaccine-induced
immunity, the attributes of effective antiviral CD8
+ T cells are still
unknown. Since they appear naturally to make effective immune
responses, ECs, both macaque and human, provide an important
example of what is possible. Here we report a new model of elite
control of immunodeficiency virus infection, Mamu-B*08-positive
macaques that effectively control infection with the pathogenic
clone SIVmac239. It will be important in future studies to refine the
Mamu-B*08 peptide binding motif, to identify all of the SIV-
derived epitopes bound by this molecule, and to test the efficacy of
Table 4. Comparison of dN and dS for the novel Mamu-B*08-restricted CD8
+ T cell epitopes in Mamu-B*08-positive and Mamu-B*08-
negative SIVmac239-infected macaques.
..................................................................................................................................................
Mamu-B*08 expression Region of viral ORFs sequenced
a Mean dN6S.E. Mean dS6S.E dN=d S?
b
positive (6 macaques) B*08-restricted epitopes
c 0.055660.0011 0.016460.0075 P,0.001
Remainder 0.007260.0011 0.004160.0015 n. s.
negative (34 macaques) B*08-restricted epitopes
c 0.002860.0008 0.001460.0007 n. s.
Remainder 0.006360.0006 0.002560.0006 P,0.001
B*08+ dN=B*08- dN?
d B*08-restricted epitopes
c P,0.001
B*08+ dS=B*08- dS?
d B*08-restricted epitopes
c n.s.
a)We sequenced the entire open reading frames (ORFs) of vif, rev,a n dnef from chronic infection or at time of necropsy in 6 Mamu-B*08-positive and 34 Mamu-B*08-
negative macaques infected with SIVmac239. We compared epitope-encoding regions to the remainder of the three ORFs using the following tests.
b)Paired t-test (2-tailed) performed to determine whether dN was equal to dS in Mamu-B*08-restricted CD8
+ T cell epitope sequences and in non-Mamu-B*08-restricted
epitope regions. (n.s.=not significant)
c)We included one amino acid N-terminal to the Nef epitopes RL10 (pos. 137–146) and RL9 (pos. 246–254) because it appeared that variation was associated with Mamu-
B*08 expression. See text and Figs. 5 and 6 for details.
d)Two-sample t-tests (2-tailed) were performed to determine whether dN and dS values were significantly higher in Mamu-B*08-positive animals than in Mamu-B*08-
negative animals. (n.s.=not significant)
doi:10.1371/journal.pone.0001152.t004
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+ T cells more directly. Interestingly,
Mamu-B*08-associated control of SIVmac239 replication may
closely parallel HLA-B27-associated control of HIV replication.
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